Bank of Canada holds key interest rate
There were no moves from the Bank of Canada Wednesday as it held its key interest rate at 2.75%. CTV's Kimberley Fowler reports.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
30 minutes ago
- CTV News
Hydro-Quebec rate hikes: Here's how much you could pay based on your home
A Hydro-Quebec truck is seen in Montreal, Sept.1, 2023. (THE CANADIAN PRESS/Christinne Muschi) Last month, Hydro-Quebec presented its rate increase requests for the next three years: 2026, 2027 and 2028. It proposed annual increases of three per cent for residential consumers and 4.8 per cent for commercial and industrial customers. For the residential sector, the proposed increase could raise an apartment's average electricity bill by $2.40 per month. For an average-sized house, that number goes up to $6.70 per month. Here is an estimate of how your household electricity bill could increase in the coming years, based on the type of dwelling, according to Noovo Info. Detached single-family house Approximate, for an annual consumption of 22,500 kWh. 2025 Annual bill: $2,400 Average monthly bill: $200 2026 Annual bill: $2,472 Average monthly bill: $206 2027 Annual bill: $2,546 Average monthly bill: $213 2028 Annual bill: $2,622 Average monthly bill: $219 Semi-detached house Approximate, for an annual consumption of 18,500 kWh. 2025 Annual bill: $1,910 Average monthly bill: $159 2026 Annual bill: $1,967 Average monthly bill: $164 2027 Annual bill: $2,026 Average monthly bill: $169 2028 Annual bill: $2,087 Average monthly bill: $174 Townhouse Approximate, based on an annual consumption of 15,500 kWh. 2025 Annual bill: $1,530 Average monthly bill: $128 2026 Annual bill: $1,576 Average monthly bill: $131 2027 Annual bill: $1,623 Average monthly bill: $135 2028 Annual bill: $1,672 Average monthly bill: $139 Apartment or condo Approximate, for an annual consumption of 12,000 kWh. 2025 Annual bill: $1,100 Average monthly bill: $92 2026 Annual bill: $1,133 Average monthly bill: $94 2027 Annual bill: $1,167 Average monthly bill: $97 2028 Annual bill: $1,202 Average monthly bill: $100 The proposed rates must be approved by Quebec's energy board, the Régie de l'énergie. Its decision is expected to come in March 2026, with the new rates taking effect on April 1. With files from The Canadian Press.
Globe and Mail
30 minutes ago
- Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, 'Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,' please visit: As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's 'Make America Healthy Again' initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) ('SGX301' or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma ('CTCL'). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin ('SGX302') into psoriasis, the company's first-in-class innate defense regulator ('IDR') technology, dusquetide ('SGX942') for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and ('SGX945') in Behçet's disease. The company's Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company's vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases ('NIAID'), the Defense Threat Reduction Agency ('DTRA') and the Biomedical Advanced Research and Development Authority ('BARDA'). For further information, visit the company's website at . About NetworkNewsWire NetworkNewsWire ('NNW') is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit
Globe and Mail
30 minutes ago
- Globe and Mail
AEye to Participate in J.P. Morgan Auto Conference
AEye, Inc. (Nasdaq: LIDR), a pioneer in high-performance lidar technology and creator of the Apollo lidar sensor, today announced that its CEO, Matt Fisch, will participate in the following conference: J.P. Morgan Auto Conference Location: New York, NY Date: August 12-13, 2025 Format: One-on-one meetings: August 12-13 Company presentation: August 13 at 2:05pm ET A live webcast of the company's presentation will be available at Webcast Link. A replay and related investor materials will also be available in the Investor Relations section of AEye's website at To request a meeting with AEye at the conference, please contact aeye@ About AEye AEye offers unique software-defined lidar solutions that enable advanced driver-assistance, vehicle autonomy, smart infrastructure, security, and logistics applications that save lives and propel the future of transportation and mobility. AEye's flagship product, Apollo, has been widely recognized for its small form factor and its ability to detect objects at up to one kilometer. In addition to Apollo as a stand-alone sensor, AEye also offers a full-stack solution through its OPTIS™ platform. OPTIS™ provides a complete system that captures a high-resolution 3D image of the world, interprets it, and provides direction to act upon what it sees in real-time.
